PERSON – Page 3

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

4 weeks ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff

4 weeks ago talkbio0Tagged 2025, 75%, 8, Fierce, Generalized, Genomics, NGM, Staff

NGM, Genomics, Fierce, 8, Generalized, Staff, 75%, 2025

Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis

1 month ago talkbio0Tagged Approved, DTC Campaign, Empowerment, Myasthenia Gravis, Generalized, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, self-administration, Syringes, United States Food and Drug Administration, Vyvgart Hytrulo

Vyvgart Hytrulo, prefilled syringe, FDA approval, self-administration, generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), DTC campaign, patient empowerment

Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit

1 month ago talkbio0Tagged cynicism, Immune response, mandates, Misinformation, Offit, Paul Offit, Urinary hesitation, Vaccines

Vaccines, Urinary hesitation, Offit, cynicism, Misinformation, Immune response, Paul Offit, mandates

Vinay Prasads FDA Appointment Anything but Status Quo

1 month ago talkbio0Tagged Anything, Appointments, Prasad, Prasad 's, Status Quo, United States Food and Drug Administration, Vaccines

United States Food and Drug Administration, Appointments, Vaccines, Prasad, Prasad ‘s, Anything, Status Quo

FDA eyes full AI integration by June as Makary touts genAI pilot success

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, DNA Integration, June, Makary, United States Food and Drug Administration

United States Food and Drug Administration, Aortic Valve Insufficiency, DNA Integration, Artificial Intelligence, Makary, June

Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff

1 month ago talkbio0Tagged 95%, gene therapy, Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular

Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular, gene therapy, 95%

In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen

1 month ago talkbio0Tagged J&J, oncology expert, Pfizer, Roche (company), United States Food and Drug Administration, UroGen

United States Food and Drug Administration, oncology expert, J&J, Pfizer, Roche (company), UroGen

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

1 month ago1 month ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

Biotech stocks plunge and industry figures left to wonder after Prasad’s FDA appointment

1 month ago talkbio0Tagged Appointments, Cell Therapy, figures, Industry, Market, Prasad, stocks, United States Food and Drug Administration

United States Food and Drug Administration, Industry, Prasad, Appointments, stocks, Cell Therapy, Market, figures